MAIA Biotechnology, Inc. (MAIA)
NYSE American · Manufacturing · Pharmaceutical preparations
$1.21−$0.0400 (−3.20%) on the dayAs of the close; data may be delayed.
MAIA price, last 12 months
Key stats
- Previous close
- $1.25
- Open
- $1.28
- Day range
- $1.20 – $1.33
- 52-week range
- $0.8700 – $3.19
- Volume
- 911K
- Avg volume (20 days)
- 627.7K
- Market cap
- $73.0M
Performance
1W−7.6%
1M−13.0%
3M−14.2%
6M−12.3%
YTD−20.9%
1Y−24.4%
vs S&P 500, 1Y−41.2 pts
Technicals and fundamentals
About MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NYSE American
- Market cap
- $73.0M